In a multicenter , double-blind randomized controlled trial in progress at three intensive care units across Denmark , we randomly assign eligible critically ill adults with acute kidney injury into a treatment ( @ mg/kg enoxaparin subcutaneously once daily ) or control arm ( @ mg enoxaparin subcutaneously once daily ) upon commencement of continuous renal replacement therapy.We calculated that with @ patients in each group , the study would have @ % power to show a @ % reduction in the relative risk of venous thromboembolism with @ mg/kg enoxaparin , at a two-sided alpha level of @ .